Form 4: Aptevo Therapeutics CFO Acquires Shares Through RSU Vesting

Aptevo Therapeutics' Chief Financial Officer, Daphne Taylor, acquired common stock through the scheduled vesting of restricted stock units.

Summary

• Daphne Taylor, SVP and Chief Financial Officer of Aptevo Therapeutics Inc. (APVO), acquired 3 shares of the company's common stock.
• This acquisition occurred on July 17, 2025, and resulted from the vesting of Restricted Stock Units (RSUs).
• The RSUs were originally granted on July 17, 2024, totaling 11 post-split units.
• The vesting is structured in three approximately equal annual installments, with this transaction representing the first installment.
• Following this transaction, Ms. Taylor directly holds 3 shares of common stock and 8 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing reports a routine vesting of restricted stock units for a key executive, which increases insider ownership and aligns management interests with shareholders. However, the number of shares acquired in this specific transaction is very small (3 shares), limiting its overall positive impact on sentiment.

Positives

• The vesting of Restricted Stock Units (RSUs) for a key executive like the CFO aligns management's long-term interests with those of shareholders.
• This transaction represents an increase in direct insider ownership, albeit a small one of 3 shares.

Negatives

• The number of shares acquired (3) is very small, which might be a consequence of a reverse stock split, and thus has a negligible direct impact on the company's share structure or market perception.

Future Outlook

The remaining 8 Restricted Stock Units (RSUs) granted to Daphne Taylor are expected to vest in future approximately equal annual installments.

Industry Context

The use of equity awards such as Restricted Stock Units (RSUs) is a standard practice in executive compensation across the biotechnology and pharmaceutical industries, designed to align the interests of management with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance.
• While RSU grants are standard, the specific number of shares vesting in this tranche (3 shares) is exceptionally low for a Chief Financial Officer, likely due to a prior reverse stock split as indicated by the 'post-splits' notation for the original grant of 11 RSUs. This makes direct quantitative comparison of this specific vesting event to typical executive compensation packages challenging without full context of the total compensation structure.

Related Party Transactions

• This transaction represents a standard compensation-related dealing between the company and a key executive (CFO) through the vesting of equity awards.

Stakeholder Impact

• Shareholders: A slight increase in insider ownership, which can be viewed positively as it aligns management's interests with shareholder value, though the quantity of shares is minimal.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Future vesting installments of the remaining 8 Restricted Stock Units (RSUs) for Daphne Taylor.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Daphne Taylor, CFO